These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9155634)

  • 41. [Losartan (LORZAAR) and Losartan/hydrochlorothiazide (LORZAAR-PLUS)--their value in hypertension therapy. Symposium on the occasion of the 103rd Session of the German Society. Wiesbaden, 7 April 1997].
    Dtsch Med Wochenschr; 1997 Sep; 122(36 Suppl Losartan):1-4. PubMed ID: 9330577
    [No Abstract]   [Full Text] [Related]  

  • 42. New angiotensin-II blocker.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
    [No Abstract]   [Full Text] [Related]  

  • 43. [Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
    Krasnikova TL
    Klin Med (Mosk); 1996; 74(3):17-21. PubMed ID: 8926692
    [No Abstract]   [Full Text] [Related]  

  • 44. [Renin-angiotensin system blockade. What can be expected from angiotensin II antagonists?].
    Waeber B; Nussberger J; Brunner H
    Rev Prat; 1992 Oct; 42(16):2066-8. PubMed ID: 1485114
    [No Abstract]   [Full Text] [Related]  

  • 45. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 46. Losartan: the first angiotensin receptor antagonist in clinical use.
    Beevers DG
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
    [No Abstract]   [Full Text] [Related]  

  • 47. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
    Ellis ML; Patterson JH
    Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Angiotensin II antagonist for heart insufficiency].
    Z Kardiol; 1997 Jun; 86(6 Suppl):1-8. PubMed ID: 9259867
    [No Abstract]   [Full Text] [Related]  

  • 49. Losartan protects the rat kidney from ischemic injury.
    Heller J; Kramer HJ; Cervenka L; Hellerová S
    Kidney Int Suppl; 1996 Jun; 55():S113-4. PubMed ID: 8743528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.
    Descombes E; Fellay G
    Ren Fail; 2000 Nov; 22(6):815-21. PubMed ID: 11104169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Losartan and angina pectoris.
    Ahmad S
    Tex Heart Inst J; 1995; 22(4):347-8. PubMed ID: 8605440
    [No Abstract]   [Full Text] [Related]  

  • 53. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats.
    Sakemi T; Baba N
    Nephron; 1993; 65(3):426-32. PubMed ID: 8289994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.
    Opsahl JA; Goldberg MR; Katz SA
    Am J Hypertens; 1995 Nov; 8(11):1090-8. PubMed ID: 8554732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug companies should not have the final say in the design of clinical trials.
    Kurtzman NA
    Am J Kidney Dis; 2001 Nov; 38(5):1113-4. PubMed ID: 11684568
    [No Abstract]   [Full Text] [Related]  

  • 58. [The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension].
    Trimarco B
    Cardiologia; 1995 Dec; 40(12 Suppl 1):193-5. PubMed ID: 8998714
    [No Abstract]   [Full Text] [Related]  

  • 59. Losartan (Cozaar).
    Baldinger S
    Conn Med; 1996 May; 60(5):281-4. PubMed ID: 8998906
    [No Abstract]   [Full Text] [Related]  

  • 60. Renal hemodynamics in essential hypertensives treated with losartan.
    Erley CM; Bader B; Scheu M; Wolf S; Braun N; Risler T
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S8-11. PubMed ID: 7781206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.